Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis.
Adult
Alleles
Endocannabinoids
/ genetics
Female
Gene-Environment Interaction
Genotype
Heterozygote
Homozygote
Humans
Male
Marijuana Smoking
/ genetics
Polymorphism, Genetic
/ genetics
Polymorphism, Single Nucleotide
Psychotic Disorders
/ complications
Risk Assessment
Schizophrenia
/ genetics
Socioeconomic Factors
Young Adult
Cannabis
Endocannabinoid system
FAAH
Psychosis
Schizophrenia
rs2295633
Journal
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
05
2018
revised:
27
03
2019
accepted:
23
04
2019
pubmed:
12
5
2019
medline:
8
8
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
Alterations of the endocannabinoid system (ECS) may play an important role in the development of schizophrenia and other psychotic disorders. Cannabis use is one of the environmental factors more repeatedly related to an increase the risk of developing a psychotic episode, while its use modifies the ECS normal function. In the present study we purposed to examine the gene by environment (GxE) interaction between 15 selected single nucleotide polymorphisms (SNPs) related to the ECS and cannabis use in a cohort of 321 patients with a first episode of psychosis (FEP) and 241 matched healthy controls. We found the fatty-acid amide hydrolase (FAAH) rs2295633 SNP genetic polymorphism was associated with a greater risk of presenting a FEP in subjects with relevant cannabis use, but not in subjects without a history of cannabis use. The probability of presenting a FEP was tenfold higher (OR: 10.69) in cannabis users who were homozygote carriers of the T allele of the FAAH rs2295633 SNP, compared to users of cannabis without this genotype. We also found that a higher a proportion of TT carriers of the FAAH rs2295633 SNP with a positive history of cannabis use was treated with high potency antipsychotic. This study has identified a GxE-environment interaction between a genetic polymorphism from the ECS and cannabis use involved in the risk of presenting a FEP. Although this preliminary data should be replicated with independent samples, our results highlight the importance of the pro-psychotic effects of exogenous cannabis use over the ECS in certain subjects.
Identifiants
pubmed: 31076188
pii: S0924-977X(19)30236-6
doi: 10.1016/j.euroneuro.2019.04.005
pii:
doi:
Substances chimiques
Endocannabinoids
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
786-794Informations de copyright
Copyright © 2019. Published by Elsevier B.V.